Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CTSO
CTSO logo

CTSO News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CTSO News

CytoSorbents (CTSO) Projects $37M Revenue for 2025, FDA Meeting Scheduled

Jan 12 2026PRnewswire

CytoSorbents Reports $37M in Q3 Sales; CEO to Join Virtual Discussion

Dec 10 2025PRnewswire

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Nov 17 2025PRnewswire

HC Wainwright & Co. Upholds Neutral Rating for Cytosorbents (CTSO)

Nov 15 2025NASDAQ.COM

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13 2025PRnewswire

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

Nov 11 2025PRnewswire

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

Oct 28 2025PRnewswire

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Sep 29 2025PRnewswire

CTSO Events

01/12 07:10
Full-Year Gross Margin Expected at Approximately 72%
Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024.
01/12 07:10
Fourth Quarter Gross Margin Expected to Reach 73%-75%
Fourth quarter gross margin is expected to be in the range of 73%-75%, compared to 71% in the fourth quarter of 2024, and 70% in the third quarter of 2025.
11/13 16:18
CytoSorbents Launches Program to Reduce Workforce and Costs
CytoSorbents announced the implementation of a strategic Workforce and cost reduction plan to further reduce costs, optimize operations, and accelerate the path to cash-flow profitability. This initiative follows a comprehensive internal review of its cost structure and operating model. As part of the strategic plan, CytoSorbents reduced its workforce by approximately 10%, reduced and realigned production and operating expenses, and now expects to reach operating cash flow break-even in Q1 2026. The company expects to record a charge of up to $900K that will include severance and other charges related to the restructuring. The estimated costs that the company expects to incur, and the timing thereof, are subject to a number of assumptions, and actual amounts may differ materially.

CTSO Monitor News

No data

No data

CTSO Earnings Analysis

No Data

No Data

People Also Watch